WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) announced the launch of “BEYOND mLM,” a disease awareness campaign and website designed to provide educational resources for patients, caregivers, and healthcare professionals affected by microcystic lymphatic malformations.
The company said the campaign, accessible at https://BEYONDmLM.com, was developed in collaboration with nonprofit and research organizations focused on vascular and lymphatic diseases.
Microcystic lymphatic malformations are a rare genetic condition involving malformed lymphatic vessels that can protrude through the skin and leak lymph fluid or bleed, often causing recurrent infections and hospitalizations.
More than 30,000 children and adults in the United States have been diagnosed with the disease, and there are currently no FDA-approved therapies.
Palvella said the campaign was created in partnership with several nonprofit organizations and clinical networks, including the Consortium of iNvestigators of Vascular AnomalieS, the Lymphangiomatosis & Gorham’s Disease Alliance, the Lymphatic Education & Research Network, the Pediatric Dermatology Research Alliance, and VAccess.org.
“These patients often lack access to educational materials written in a way that is accessible and practical,” said Dr. Michael Kelly, a pediatric hematologist-oncologist at the Cleveland Clinic’s Vascular Anomalies Program and executive director of the Lymphangiomatosis & Gorham’s Disease Alliance.
Kelly said the initiative is intended to provide resources for patients and caregivers while helping healthcare providers better understand the condition.
The website includes information about the biology of the disease and its medical and psychosocial impacts, and the company said additional content such as patient stories and expert insights will be added.
“Microcystic lymphatic malformations are rare, complex, and often misunderstood,” said Ashley Kline, chief commercial officer of Palvella Therapeutics.
She said the campaign aims to provide accessible information and support for the patient community.
Palvella Therapeutics is a clinical-stage biotechnology company developing treatments for rare skin diseases and vascular malformations.
Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is being studied as a potential treatment for microcystic lymphatic malformations and related conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.